ING Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

ING Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,050	Closed	-$402K	–	787
2019 Q2	$402K	Buy	+5,050	New	+$452K	0.01%	587
2018 Q3	–	Sell	-27,500	Closed	-$2.31M	–	882
2018 Q2	$2.31M	Buy	+27,500	New	+$2.01M	0.04%	205
2017 Q3	–	Sell	-10,169	Closed	-$1.23M	–	931
2017 Q2	$1.23M	Buy	10,169 +7,769	+324%	+$900K	0.02%	282
2017 Q1	$271K	Sell	2,400 -17,000	-88%	-$1.98M	﹤0.01%	521
2016 Q4	$2.12M	Buy	+19,400	New	+$2.31M	0.04%	211
2016 Q3	–	Sell	-5,900	Closed	-$842K	–	609
2016 Q2	$842K	Sell	5,900 -2,350	-28%	-$343K	0.01%	272
2016 Q1	$1.06M	Sell	8,250 -250	-3%	-$29.5K	0.01%	288
2015 Q4	$1.27M	Buy	+8,500	New	+$1.44M	0.01%	475
2015 Q2	–	Sell	-1,000	Closed	-$282K	–	752
2015 Q1	$282K	Buy	+1,000	New	+$217K	﹤0.01%	747

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ING Group's ICPT Position: Q3 2019 in Review

ING Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2019, closing a stake of 5,050 shares — an estimated $402K sold.

ING Group first reported a position in ICPT in Q1 2015 and held it in 9 quarters. The position peaked at $2.31M in Q2 2018. 188 funds tracked by Wall St. Rank hold ICPT as of Q3 2019.

ING Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
ING Group sold 5,050 Intercept Pharmaceuticals, Inc. shares in Q3 2019, an estimated $402K.
ING Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 9 quarters.
ING Group's Intercept Pharmaceuticals, Inc. position peaked at $2.31M in Q2 2018.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2019.

Based on ING Group's 13F filing for Q3 2019, filed 8 Nov 2019.